01558 HEC CJ PHARM
- 11.660
- -0.360-3.00%
HEC CJ PHARM News
Big Bank Rating | Damo: Upgraded Dongyangguang Changjiang Pharmaceutical's target price to HK$13.2 to “increase” the rating
Big Bank Rating | Damo: Raise Dongyang Pharmaceutical's target price to HK$12.6 to maintain “gain” rating
Dongyang Changjiang Pharmaceutical (01558.HK): 1H23 performance exceeded expectations, Kewei recovered significantly
Damo: Maintaining Dongyangguang Changjiang Pharmaceutical's (01558) “Increase Holdings” Rating, Raising the Target Price to HK$12.5
Dongyang Pharmaceutical (01558.HK): Sales have recovered significantly, and revenue in 2022 has greatly exceeded expectations
Dongyang Pharmaceutical (1558.HK): Coway resumed strong growth last year, and sales are expected to reach new highs this year
Big Bank Ratings | Daimo: Shengdong Sunshine Pharmaceutical's rating was raised to the target price of “increase holdings” to HK$12
Changes in Hong Kong stocks | Dongguang Pharmaceutical rose more than 9% in the intraday market, hit a 20-month high, and institutions soared their target prices
Daimo: Yudong Sunshine Pharmaceutical (01558) “increase its holdings” rating target price is HK$12
Dongyang Pharmaceutical (01558.HK): Core product sales pick up, 1H22 performance exceeds expectations
Dongyang Pharmaceutical (01558.HK): Core products continue to suffer, 1H21 performance falls short of expectations
Dongguang Pharmaceutical (01558.HK): Products are getting richer and starting again
Dongguang Pharmaceutical (01558.HK): Core varieties affected by the epidemic; expected to recover in the second half of the year
Dongyang Pharmaceutical (1558.HK): Weak third quarter report cites our cautious opinion; maintains holding ratings
Dongyang Pharmaceutical (01558.HK): Difficult to get a revaluation; downgraded to holding
Dongguang Pharmaceutical (1558.HK): Kewei continues to grow and product structure upgrades are worth looking forward to
Dongyang Pharmaceutical (01558.HK): The impact of the COVID-19 pandemic on Coway sales is gradually weakening
Dongyang Pharmaceutical (01558.HK) 2020 Q1 Quarterly Report Review: Performance Meets Expectations, and Progress of New Drugs Under Research Accelerated
Dongyang Light Drug (1558.HK): multi-level sales network has become an expectation for new products to be realized one after another.
Dongyang Pharmaceutical (01558.HK): Kewei continues to grow strongly; looking forward to the release of new products
Analysis
Price Target
No Data
